{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:14:25Z","timestamp":1778210065852,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00210-025-04966-3","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:26:53Z","timestamp":1769232413000},"page":"9777-9788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I randomized double-blind parallel-group study: pharmacokinetics, safety, and immunogenicity of pertuzumab biosimilar SYSA1901 in healthy Chinese males"],"prefix":"10.1007","volume":"399","author":[{"given":"Yucai","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renpeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"7","key":"4966_CR1","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","volume":"28","author":"J Baselga","year":"2010","unstructured":"Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28(7):1138\u20131144. https:\/\/doi.org\/10.1200\/JCO.2009.24.2024","journal-title":"J Clin Oncol"},{"key":"4966_CR2","doi-asserted-by":"publisher","unstructured":"Boix-Perales H, Borregaard J, Jensen KB, Ersboll J, Galluzzo S, Giuliani R ... Pignatti F (2014) The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 19(7):766\u2013773. https:\/\/doi.org\/10.1634\/theoncologist.2013-0348","DOI":"10.1634\/theoncologist.2013-0348"},{"issue":"6","key":"4966_CR3","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/cpt.3033","volume":"114","author":"CA Cheng","year":"2023","unstructured":"Cheng CA, Jiang AL, Liu YR, Chang LC (2023) Investigation of immunogenicity assessment of biosimilar monoclonal antibodies in the United States. Clin Pharmacol Ther 114(6):1274\u20131284. https:\/\/doi.org\/10.1002\/cpt.3033","journal-title":"Clin Pharmacol Ther"},{"key":"4966_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.660541","volume":"12","author":"Y Cui","year":"2021","unstructured":"Cui Y, Cui D, Ren X, Chen X, Liu G, Liu Z, Wang Y, Qu X, Zhao Y, Yang H (2021) Pharmacokinetics, immunogenicity and safety study for SHR-1309 injection and Perjeta(R) in healthy Chinese male volunteers. Front Pharmacol 12:660541. https:\/\/doi.org\/10.3389\/fphar.2021.660541","journal-title":"Front Pharmacol"},{"issue":"3","key":"4966_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.7399\/fh.11376","volume":"44","author":"R Diaz-Acedo","year":"2020","unstructured":"Diaz-Acedo R, Artacho-Criado S, Galvan-Banqueri M, Lopez-Alvarez P (2020) Real world study of pertuzumab-trastuzumabchemotherapy versus trastuzumab-chemotherapy in neoadjuvant treatment of breast cancer. Farm Hosp 44(3):96\u201399. https:\/\/doi.org\/10.7399\/fh.11376","journal-title":"Farm Hosp"},{"key":"4966_CR6","unstructured":"EMA, E. M. A. (2012). Guideline on similar biological medicinal products containing monoclonal antibodies \u2013 non-clinical and clinical issues (EMA\/CHMP\/BMWP\/403543\/2010). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical-and-clinical-issues_en.pdf"},{"key":"4966_CR7","unstructured":"EMA, E. M. A. (2013). Perjeta | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/perjeta"},{"key":"4966_CR8","unstructured":"FDA, F. A. D. A. (2012). 2012 Notifications. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/2012-notifications"},{"issue":"4","key":"4966_CR9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00280-014-2560-3","volume":"74","author":"A Garg","year":"2014","unstructured":"Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cort\u00e9s J, McNally V, Ross G, Visich J, Lum B (2014) Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. Cancer Chemother Pharmacol 74(4):819\u2013829. https:\/\/doi.org\/10.1007\/s00280-014-2560-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4966_CR10","unstructured":"Genentech (2012). PERJETA\u00ae (pertuzumab) injection, for intravenous use. https:\/\/www.gene.com\/download\/pdf\/perjeta_prescribing.pdf"},{"issue":"3","key":"4966_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14712598.2017.1282944","volume":"17","author":"L Gerratana","year":"2017","unstructured":"Gerratana L, Bonotto M, Bozza C, Ongaro E, Fanotto V, Pelizzari G, Puglisi F (2017) Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Expert Opin Biol Ther 17(3):365\u2013374. https:\/\/doi.org\/10.1080\/14712598.2017.1282944","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"4966_CR12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A, Siegel RL (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72(6):524\u2013541. https:\/\/doi.org\/10.3322\/caac.21754","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4966_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100433","volume":"7","author":"V Guarneri","year":"2022","unstructured":"Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, Girardi F (2022) Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. ESMO Open 7(2):100433. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100433","journal-title":"ESMO Open"},{"issue":"1","key":"4966_CR14","doi-asserted-by":"publisher","first-page":"2523561","DOI":"10.1080\/07853890.2025.2523561","volume":"57","author":"Y Li","year":"2025","unstructured":"Li Y, Wang Y, Yang C, Zhao N, Wang X (2025) A phase I, randomized, double-blind, parallel, single-dose pharmacokinetic study to evaluate the biosimilarity of KM118 (proposed pertuzumab biosimilar) with reference pertuzumab (Perjeta((R))) in healthy male subjects. Ann Med 57(1):2523561. https:\/\/doi.org\/10.1080\/07853890.2025.2523561","journal-title":"Ann Med"},{"issue":"2","key":"4966_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/14712598.2021.1988567","volume":"22","author":"G Liu","year":"2022","unstructured":"Liu G, Xu Z, Yang W, Xue J, Wang Y, Liu Z, Cui Y, Qu X, Chang T, Yu S, Cheng Y, Zhou Y, Chen J, Ren Q, Wang W, Deng Q, Wang Z, Yang H (2022) A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta(R) in healthy Chinese male subjects. Expert Opin Biol Ther 22(2):187\u2013195. https:\/\/doi.org\/10.1080\/14712598.2021.1988567","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"4966_CR16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im Y-H, Kuemmel S, El-Saghir N, O\u2019Regan R, Gasch C, Solovieff N, Wang C, Wang Y, Chakravartty A, Ji Y, Tripathy D (2022) Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res 28(5):851\u2013859. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3032","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4966_CR17","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s11095-006-0205-x","volume":"23","author":"CM Ng","year":"2006","unstructured":"Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D (2006) Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 23(6):1275\u20131284. https:\/\/doi.org\/10.1007\/s11095-006-0205-x","journal-title":"Pharm Res"},{"key":"4966_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.953641","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun Y, Yang H, Yang X, Yang S, Guo C, Chen H, Cui C, Xiang Y, Yang G, Huang J (2022) A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta((R)) in healthy male subjects. Front Pharmacol 13:953641. https:\/\/doi.org\/10.3389\/fphar.2022.953641","journal-title":"Front Pharmacol"},{"issue":"3","key":"4966_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"4966_CR20","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724\u2013734. https:\/\/doi.org\/10.1056\/NEJMoa1413513","journal-title":"N Engl J Med"},{"key":"4966_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102339","volume":"104","author":"D Trapani","year":"2022","unstructured":"Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, Anderson BO, Curigliano G (2022) Global challenges and policy solutions in breast cancer control. Cancer Treat Rev 104:102339. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102339","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"4966_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40259-022-00534-w","volume":"36","author":"J Yang","year":"2022","unstructured":"Yang J, Lin L, Long Q, Zhang Q, Sun G, Zhou L, Wang Q, Zhu J, Li F, Hu W (2022) HLX11, a proposed pertuzumab biosimilar: pharmacokinetics, immunogenicity, and safety profiles compared to three reference biologic products (US-, EU-, and CN-approved pertuzumab) administered to healthy male subjects. BioDrugs 36(3):393\u2013409. https:\/\/doi.org\/10.1007\/s40259-022-00534-w","journal-title":"BioDrugs"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04966-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04966-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04966-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:44:30Z","timestamp":1778208270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04966-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4966"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04966-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was designed and conducted in accordance with the ethical and scientific principles outlined in the Declaration of Helsinki, the Good Clinical Practice (GCP) guidelines issued by the International Council for Harmonisation, as well as the GCP regulations and relevant provisions issued by the National Medical Products Administration (NMPA). The Ethics Committee of the Second Hospital of Anhui Medical University approved the study protocol and all amendments (approval number:SL-YW2021-126).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Prior to enrolling in this study, investigators fully informed each participant of the study\u2019s objectives, methodology, study drug effects, expected benefits, potential adverse reactions, and risks\u2014ensuring understanding of their rights, as well as the risks and benefits of participation. After careful consideration, all participants signed the informed consent form, and no study-specific procedures were conducted before obtaining a valid form from each participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}